- Home
- MSB vs ALT Comparison
MSB vs ALT Comparison
Compare MSB & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MSB | ALT |
|---|---|---|
| Founded | 1961 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Mining | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 411.8M | 421.5M |
| IPO Year | 1995 | 2005 |
Fundamental Metrics
Financial Performance| Metric | MSB | ALT |
|---|---|---|
| Price | $31.46 | $3.43 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 40.3K | ★ 2.5M |
| Earning Date | 04-24-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.05% | N/A |
| EPS Growth | ★ 391.29 | 25.37 |
| EPS | ★ 0.85 | N/A |
| Revenue | ★ $98,595,651.00 | $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $37.17 | ★ N/A |
| Revenue Growth | ★ 331.26 | 105.00 |
| 52 Week Low | $22.55 | $2.87 |
| 52 Week High | $42.38 | $7.73 |
Technical Indicators
Market Signals| Indicator | MSB | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 51.02 | 48.32 |
| Support Level | $30.18 | $3.40 |
| Resistance Level | $33.00 | $3.54 |
| Average True Range (ATR) | 1.52 | 0.16 |
| MACD | 0.14 | 0.06 |
| Stochastic Oscillator | 50.64 | 82.84 |
Price Performance
Historical ComparisonAbout MSB Mesabi Trust
Mesabi Trust operates as a royalty trust in the United States. The company is involved in the conservation and protection of its assets. The company's principally wholly-owned segment is the iron ore mining segment, which generates income from the Peter Mitchell Mine, an iron mine located near Babbitt, Minnesota, at the eastern end of the Mesabi Iron Range.
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.